Cortisol is a steroid hormone that is normally secreted by the adrenal cortex in response to ACTH. It exerts its action by binding to nuclear receptors, which then act upon chromatin to regulate gene expression, producing effects throughout the body.
Hydrocortisone and cortisone acetate, like cortisol, have mineralocorticoid effects that become excessive at higher doses (eTable 26–2). Other synthetic corticosteroids such as prednisone, dexamethasone, and deflazacort (an oxazoline derivative of prednisolone) have minimal mineralocorticoid activity. Anticonvulsant drugs (eg, phenytoin, carbamazepine, phenobarbital) accelerate the metabolism of corticosteroids other than hydrocortisone, making them significantly less potent. Megestrol, a synthetic progestin, has slight corticosteroid activity that becomes significant when administered in high doses for appetite stimulation.
eTable 26–2.Systemic versus topical activity of corticosteroids.1 ||Download (.pdf) eTable 26–2. Systemic versus topical activity of corticosteroids.1
| ||Systemic Activity ||Topical Activity |
|Prednisone ||4–5 ||1–2 |
|Triamcinolone ||5 ||1 |
|Triamcinolone acetonide ||5 ||40 |
|Dexamethasone ||30–120 ||10 |
|Betamethasone ||30 ||5–10 |
|Betamethasone valerate ||— ||50–150 |
|Methylprednisolone ||5 ||5 |
|Fluocinolone acetonide ||— ||40–100 |
|Flurandrenolide ||— ||20–50 |
|Deflazacort ||3–4 ||— |
Prolonged treatment with high-dose corticosteroids causes toxic effects that can be life threatening. Besides oral and parenteral administration, transdermal and inhaled corticosteroids have some systemic absorption and can cause similar adverse effects. Patients should be thoroughly informed of the major possible side effects of treatment: insomnia, cognitive and personality changes, weight gain with central obesity, skin thinning and bruising, striae, muscle weakness, polyuria, renal calculi, diabetes mellitus, glaucoma, cataracts, sex hormone suppression, candidiasis, and opportunistic infections. Prolonged high-dose corticosteroids also increase the risk of hypertension, dyslipidemia, myocardial infarction, stroke, atrial fibrillation or flutter, and heart failure. Gastric ulceration is more common with high-dose corticosteroids, particularly when patients take NSAIDs concurrently. Prolonged oral, inhaled, intravenous, or high-dose topical corticosteroid therapy commonly suppresses pituitary ACTH secretion, causing secondary adrenal insufficiency. High-dose inhaled corticosteroids predispose to oral thrush and pulmonary nontuberculous mycobacterial infection. To reduce risks, the dosage and duration of corticosteroid administration must be minimized. Immediately following inhaled corticosteroids, proper mouth-washing and gargling can reduce systemic absorption.
Most corticosteroids (dexamethasone, prednisone, hydrocortisone, deflazacort, budesonide) are metabolized by the enzyme CYP34A. When drugs that inhibit CYP34A are administered along with even modest doses of corticosteroids (oral, inhaled, intravenous), the blood levels of the corticosteroids rise and can cause iatrogenic Cushing syndrome and secondary adrenal insufficiency. Medications that strongly inhibit CYP34A include itraconazole, ketoconazole, and nefazodone. Other strong CYP34A inhibitors include protease inhibitors and cobicistat that is an antiretroviral booster for the treatment of patients with HIV.
In pregnancy, corticosteroids taken by the mother are transmitted across the placenta to the fetus, causing adverse effects on fetal growth and development as well as childhood cognition and behavior. Therefore, ...